Market Overview:
The UK Dry Eye Treatment Market size is expected to grow from USD 135.84 million in 2022 to USD 184.90 million by 2030, at a CAGR of 3.93% during the forecast period (2023-2030).
Keratoconjunctivitis sicca, also known as dry eye, is a condition when there is insufficient tear production to moisten the eyes. This could be a sign of either low tear production or quick evaporation of the tear film on the eye's surface, which can be caused by several situations. The rise in the senior population, which is more susceptible to various eye ailments like dry eye, and the prevalence of diseases like diabetes, which influence eye function, are two factors that have contributed to the expansion of the UK dry eye treatment market. Another significant reason fueling the market's expansion is the promising number of medications in development for dry eye disease (DED). The prevalence of dry eye illness has increased nationwide as a result of the country's aging population.
Top Key Players Covered In The UK Dry Eye Treatment Market:
- Allergan plc (Ireland)
- Bausch and Lomb Pvt Ltd (Canada)
- Santen Pharmaceutical Co. Ltd (Japan)
- Otsuka Pharmaceutical Co Ltd (Japan)
- Teva Pharmaceutical Industries Ltd (Israel)
- Johnson & Johnson Services Inc (US)
- Novartis AG(Switzerland)
- I-MED Pharma (Canada)
- Lenstore (UK)
- Vision Direct (UK) and Other Major Players.
Market Dynamics and Factors:
According to a 2018 study in PubMed, epidemiological research from the Women's Health Study and Physician's Health found that the prevalence of dry eyes increases in both men and women around the age of 50, with women experiencing it more frequently than men do. The reported prevalence of tear malfunction ranges from 2% to 14.2%. Due to lacrimal gland dysfunction, altered reflex secretion decreased corneal sensitivity, or inflammatory lacrimal gland destruction, older persons are more vulnerable to insufficient tear production. The UK dry eye market is anticipated to develop due to the aging population's increased susceptibility to various eye ailments.
Because dry eye illness is becoming more common and because there are more medications in the pipeline to treat it, emerging markets are expected to present potential growth prospects for market players in the UK during the projected period. Market participants for dry eyes in the UK are vying for better patient care. Also, a lot of newly established market players are using tactics like mergers and acquisitions to broaden their product offerings through the introduction of new goods and partnerships with established companies.
UK Dry Eye Treatment Market Report Highlight:
- By Product, the Liquid-drop segment is anticipated to lead the growth of the UK Dry Eye Treatment market in the forecasted timeframe. Liquid drops are saline-containing drops for the ocular route of administration. The liquid drop contains steroids, antihistamines, sympathomimetics, beta receptor blockers, parasympathomimetic, parasympatholytic, prostaglandins, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, antifungals, or topical anesthetics. Liquid drops are generally safe for patients to use.
- By Drugs, the Anti-Inflammatory drug segment is expected to have the highest share of the UK Dry Eye Treatment market over the projected period. They are used for reducing dry eyes and maintaining moisture in the eye, anti-inflammatory drug is majorly used in eye treatment in the UK because of their property of reducing pain and itching of eyes.
- By Distribution channel, the retail pharmacy segment is set to develop at the highest CAGR during the forecasted timeframe. A retail Pharmacy is a store where the general public can get their prescriptions filled. Retail pharmacies provide dry eye drugs, drops, and ointments to patients.
Key Industry Development:
- In December 2023, EyeSight Therapeutics has achieved a significant milestone with the successful completion of a Phase 1b/2a clinical trial for their groundbreaking topical treatment, "EYS-601." The trial showcased not only the treatment's impeccable safety profile but also revealed promising preliminary efficacy in alleviating dry eye symptoms.
- In October 2023, Allergan (a AbbVie company): Received FDA approval for "Restasis® Microdose (cyclosporine ophthalmic emulsion)," a lower-dose formulation of their flagship dry eye medication, aimed at reducing potential side effects.
UK Dry Eye Treatment Market Segmentation:
By Product
- Liquid Drops
- Gel
- Liquid Wipes
- Eye Ointment
By Drug
- Artificial Lubricant Eye Drops
- Anti-Inflammatory Drugs
- Autologous Serum Eye Drops
By Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- Others
